MetLife Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,064
| Closed | -$62.5K | – | 2850 |
|
|
2023
Q4 | $62.5K | Buy |
1,064
+159
| +18% | +$8.94K | ﹤0.01% | 2754 |
|
|
2023
Q3 | $39.4K | Buy |
905
+2
| +0.2% | +$71 | ﹤0.01% | 2848 |
|
|
2023
Q2 | $32.6K | Sell |
903
-21
| -2% | -$865 | ﹤0.01% | 2913 |
|
|
2023
Q1 | $34.4K | Buy |
924
+2
| +0.2% | +$90 | ﹤0.01% | 2743 |
|
|
2022
Q4 | $41.8K | Buy |
922
+37
| +4% | +$2.39K | ﹤0.01% | 2773 |
|
|
2022
Q3 | $61.8K | Sell |
885
-21
| -2% | -$1.55K | ﹤0.01% | 2748 |
|
|
2022
Q2 | $60.8K | Sell |
906
-1,491
| -62% | -$94.8K | ﹤0.01% | 2793 |
|
|
2022
Q1 | $197K | Buy |
+2,397
| New | +$245K | ﹤0.01% | 2360 |
|
|
2021
Q2 | – | Sell |
-15,963
| Closed | -$2.73M | – | 2507 |
|
|
2021
Q1 | $2.73M | Sell |
15,963
-1,048
| -6% | -$207K | 0.03% | 721 |
|
|
2020
Q4 | $3.74M | Buy |
17,011
+1,379
| +9% | +$298K | 0.04% | 505 |
|
|
2020
Q3 | $2.6M | Sell |
15,632
-544
| -3% | -$74.4K | 0.03% | 611 |
|
|
2020
Q2 | $1.85M | Buy |
16,176
+3,521
| +28% | +$341K | 0.02% | 748 |
|
|
2020
Q1 | $973K | Buy |
12,655
+665
| +6% | +$59.6K | 0.01% | 911 |
|
|
2019
Q4 | $1.55M | Hold |
11,990
| – | – | 0.02% | 908 |
|
|
2019
Q3 | $934K | Buy |
11,990
+751
| +7% | +$70.5K | 0.01% | 1105 |
|
|
2019
Q2 | $1.16M | Buy |
11,239
+1,662
| +17% | +$129K | 0.01% | 1046 |
|
|
2019
Q1 | $702K | Buy |
9,577
+983
| +11% | +$66.9K | 0.01% | 1247 |
|
|
2018
Q4 | $365K | Hold |
8,594
| – | – | ﹤0.01% | 1553 |
|
|
2018
Q3 | $405K | Hold |
8,594
| – | – | ﹤0.01% | 1663 |
|
|
2018
Q2 | $424K | Buy |
+8,594
| New | +$325K | 0.01% | 1505 |
|
Other funds holding MRTX
MetLife Investment Management's MRTX Position: Q1 2024 in Review
MetLife Investment Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,064 shares — an estimated $62.5K sold.
MetLife Investment Management first reported a position in MRTX in Q2 2018 and held it in 20 quarters. The position peaked at $3.74M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- MetLife Investment Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- MetLife Investment Management sold 1,064 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $62.5K.
- MetLife Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 20 quarters.
- MetLife Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $3.74M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on MetLife Investment Management's 13F filing for Q1 2024, filed 14 May 2024.